BioCentury
ARTICLE | Distillery Therapeutics

ZDHHC7 and LYPLA2 identified as targets in Crohn’s, ulcerative colitis

October 27, 2020 7:55 PM UTC

DISEASE CATEGORY: Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD); Crohn’s disease...

BCIQ Company Profiles

Cornell University

BCIQ Target Profiles

Lysophospholipase 2 (LYPLA2)